
USEFUL OVERVIEW IN ADOLESCENT CONTRACEPTION

NANCY SOKKARY 2019

No conflicts of Interest or disclosures Nexplanon Trainer







Congenital Anomalies of the Uterus/Vagina Congenital Malformations of the Vulva Transgender Adolescent Medicine Differences in Sexual Development

Common Gynecologic Conditions

Adnexal Masses, Cysts and Tumors

Contraception

Hirsutism

Genital Trauma

Sexually Transmitted Infections

Pediatric vulvar issues

Breast Abnormalities

Puberty and Menstruation

Disorders of Puberty (Delayed or Precocious)

First Pelvic Exam

Menstrual suppression

Dysmenorrhea/Endometriosis

Menstrual Irregularities

Polycystic Ovary Syndrome

Premature Ovarian Insufficiency

(PMS)/(PMDD)

CONTRACEPTION: Objectives

General Principals

Counseling

Modes of Contraception

- Long acting reversible contraception
- Oral
- Non-Oral combined
- Injectable
 - *efficacy based on weight

Pregnancy Complications

- Insufficient prenatal care
- Low birth weight*
- Preterm Delivery*
- Less likely to breastfeed

Teen Pregnancy Outcomes


Future for mother


- Postpartum depression
- Less likely to graduate high school and go to college
- Intimate partner violence
- 18% with experience second pregnancy before age 20

Future for infant

- Developmental delay
- More likely to be incarcerated
- Poor school performance
- Teen pregnancy

Teen Pregnancy





https://www.cdc.gov/teenpregnancy/about/index.htm

https://www.healthypeople.gov/2020/data/Chart/4467?category=1&by=Total&fips=-1

GEORGIA CAMPAIGN FOR ADOLESCENT POWER & POTENTIAL

Education • Prevention • Action For Adolescent Health







Sex ed, teen pregnancy to get bigger focus in new Bibb curriculum



Rape: O.C.G.A. 16-6-1 Code Sections Statutory Rape: O.C.G.A. 16-6-3 Rape: Any man who forcibly uses his penis to penetrate a female's vagina Elements of Rape against her will. This law only applies to females. A husband can rape his wife in Georgia. Statutory Rape: Sexual intercourse with any person under the age of 16 Elements of years who is not your spouse. Statutory Rape Romeo and Juliet Provision: If the victim is 14-16 years old and the defendant is either 18 years old or no more than four years older than the victim, he or she will be guilty of a misdemeanor. Penalty for Rape Death penalty, life in prison without parole, or minimum of 25 years in prison followed by lifetime probation. Statutory Rape: Felony if under 21 years old, 1-20 yrs in prison. If over Penalty for 21 years old, 10-20 yrs in prison and mandatory sex offender registration. Statutory Rape Romeo and Juliet Penalty: Misdemeanor u p to 1 yr. in jail, probation,

fines, possible community service, and a possible "stay away" order.

1-800-GACHILD


Laws

STATE	SERVICES	STI SERVICES	PRENATAL CARE	ADOPTION	MEDICAL CARE FOR MINOR'S CHILD	ABORTION SERVICES
Alabama	All†	All*	All	All	All	Parental Consent
Alaska	All	All	All		All	Parental Notice
Arizona	All	All		All		Parental Consent
Arkansas	All	All*	All		All	Parental Consent
California	All	All	All	All		▼ (Parental Consent)
Colorado	All	All	All	All	All	Parental Notice
Connecticut	Some	All		Legal counsel	All	All
Delaware	All*	All*	All*	All	All	Parental Notice [‡]
Dist. of Columbia	All	All	All	All	All	All
Florida	Some	All	All		All	Parental Notice
Georgia	All	All*	All	All	All	Parental Notice


Guttmacher Institute. An overview of minors' consent law: State Policies in Brief. www.guttmacher.org/statecenter/spibs, accessed 2019.

Medical Eligibility Criteria for Contraception

Key: 1 No restriction (method can be used) 3 Theoretical or proven risks usually outweigh the advantages 4 Unacceptable health risk (method not to be used)








Medical Eligibility Criteria

Quick Start



Condoms

Use them

The rate of dual use among adolescents is 22.8%, and is lowest among LARC users



Eisenberg DL, Allsworth JE, Zhao Q, et al. Correlates of dualmethod contraceptive use: An analysis of the National Survey of Family Growth (2006-2008). Infect Dis Obstet Gynecol 2012;

Counseling: AAP Policy

PEDIATRICS[®]

OFFICIAL LOURNAL OF THE AMERICAN ACADEMY OF PEDIATRICS

Pediatricians should counsel about and ensure access to a broad range of contraceptive services ...describing the most effective methods first.

Contraception for Adolescents COMMITTEE ON ADOLESCENCE Pediatrics 2014;134;e1244; originally published online September 29, 2014; DOI: 10.1542/peds.2014-2299

Counseling

ACOG COMMITTEE OPINION

Number 710 • August 2017


Committee on Adolescent Health Care

This Committee Opinion was developed by the American College of Obstetricians and Gynecologists' Committee on Adolescent Health Care in collaboration with committee member Karen R. Gerancher, MD.

Counseling Adolescents About Contraception

EFFECTIVENESS OF FAMILY PLANNING METHODS'

*The percentages indicate the number out of every 100 women who experienced an unintended pregnancy within the first year of typical use of each contraceptive method.



Other Methods of Contraception: (1) Lactational Amenorrhea Method (LAM): is a highly effective, temporary method of contraception; and
(2) Emergency Contraception: emergency contraceptive pills or a copper ILIO after unprotected intercourse substantially reduces risk of pregnancy.

Adapted from World Health Organization (WHIC) Department of Reproductive Health and Research, Johns Hopkins Bloomberg Scholer Hollic Health-Center for Communication Programs (ICCP). Knowledge for health project.

Family planning a global handbook for providers (2011 update), Bultomer, MiC, Genera, Switzerland. (CV) and WHIC), 2011; and Trussell J. Comtraceptive failure in the United States. Contraception 2011;83:997–464.



Bedsider.org



Stayteen.org



Contraception

Most common type of contraception used by adolescent=least effective

- Combined Oral Contraceptive
- Condom
- With drawl

Contraceptive Effectiveness

Proportion of women who will become pregnant over one year of use, by method

Method	Perfect use	Typical use
Implant	0.05	0.05
Vasectomy (male sterilization)	0.10	0.15
Intrauterine device (IUD)		
Levonorgestrel-releasing	0.2	0.2
Copper-T	0.6	0.8
Tubal (female) sterilization	0.5	0.5
Injectable	0.2	6
Pill	0.3	9
Vaginal ring	0.3	9
Patch	0.3	9
Diaphragm	6	12
Sponge**	9/20	12/24
Male condom	2	18
Female condom	5	21
Withdrawal	4	22
Fertility awareness methods***	0.4-5	24
Spermicides	18	28
Emergency contraception	*	*
No method	85	85

Notes: u = unavailable. "Perfect use" denotes effectiveness among couples who use the method both consistently and correctly; "typical use" refers to effectiveness experienced among all couples who use the method (including inconsistent and incorrect use). "The effectiveness of emergency contraception (EC) is not measured on a one-year basis like other methods. EC is

Contraception

Long Acting Reversible Contraception=LARC

- Implantable method
- IUDs
 - o Copper, Mirena, Skyla, Lilleta, Kyleena





Contraception

Continuation rate of LARC at 12 months=81%

Continuation rate of short acting methods=47%

Failure rate of LARC=0.05-.08%

Failure rate of short acting combined methods=1-9%




Duration

Brand Name	Medication and Device Type (Dose)	Initial Rate of Release (micrograms/ day)	FDA- approved Duration of Use	Potential Efficacy Beyond FDA-approved Duration	ldentifying Character- istics	Size of Device (Horizontal x Vertical, mm)	Inserter Tube Diameter (mm)	Percentage of Women Experiencing an Unintended Pregnancy in the First Year of Use (Typical Use)*
Kyleena	LNG-IUD (19.5 mg)	17.5	5 years	N/A	Blue strings; silver ring	28 x 30	3.8	0.20†
Liletta	LNG-IUD (52 mg)	19.5	4 years	+1 year [‡]	Blue strings	32 x 32	4.4	0.20†
Mirena	LNG-IUD (52 mg)	20	5 years	+2 years ^{§,}	Gray strings	32 x 32	4.4	0.20 [†]
Skyla	LNG-IUD (13.5 mg)	14	3 years	N/A	Gray strings; silver ring	28 x 30	3.8	0.20 [†]
Paragard	Copper T380A IUD (380 mm²)	NA	10 years	+2 years [§]	White strings	32 x 36	4.01	0.80
Nexplanon/ Implanon	Etonogestrel single-rod contraceptive implant (68 mg)	60-70	3 years	+1-2 years	N/A	40 x 2	N/A	0.05

ACOG CO #735: Adolescent and LARC: Implants and IUD

Implantable method

- Effective for 3-5 years
- 68mg etnogesterel
- No SS difference in efficacy based on weight
- Decrease blood loss and dysmenorrhea
- No effect on bone mineral density
- Specific training required
- BREAKTHROUGH BLEEDING



Breakthrough bleeding

- COUNSELING
- NSAIDs
 - High dose 5-7 days
- Combined oral contraceptive
 - 20-35mcg pill 1-3 months
- Estrogen
 - 2mg estradiol po x 7 days
- Doxycycline
 - 100mg BID x5 days
- Tranexamic Acid
 - 650mg BID x5da



Intrauterine Device

Safety in adolescent

- No increase risk of infertility
- May be inserted without difficulty
- Possible increased risk of expulsion
- Infection
 - Risk of PID 0-5%
 - Highest if active infection when IUD is placed

Intrauterine Device

Levonorgestrel: 5-7 year

- Mirena
- Liletta
- Effective for treating HMB, dysmenorrhea, endometriosis, hyperplasia
- No difference based on weight

5 year

Kyleena*

3 year


Skyla*



Intrauterine Device

Copper

- 10-12 years
- Hormone free
- May increase pain/cramping
- May be used as emergency contraception



Oral Contraception

Combined

- 50mcg
- 30mcg
- Lo-dose
- Drospirenone containing
- Triphasic

Progesterone only***

No difference in efficacy among obese patients (kind of)

Combined COC

Sprintec/Orthocyclin

Monophasic: .3/.35 estrogen/varying types of progesterone

Necon, Ovral

Monophasic: 50mcg

Refractory bleeding

Low dose pill

Loestren, Lo-LoEstren

- 10-25mcg of estrogen
- May have decrease side effects
- Efficacy is equivalent
- +/- increased BTB

Drospirenone containing COC

Yasmin, Yaz, Gianvi, Ocella, Zarah


- PCOS
- Has anti-androgenic affect
- Small diuretic affect
- PMS/PMDD
- 24/4 cycle

FDA: association with increase r/o thrombo-embolism but data not strong enough to conclude causality

Triphasic

Why?

- No difference in breakthrough bleeding
- No difference in discontinuation rate



Breast Cancer Update

Prospective Cohort study of 1.8 million Danish women

- Followed for 11 years
- Relative risk among current or recent users;
 - 1.20 [1.14 to 1.26]
 - 1 extra breast cancer per 7960 women per year
 - May be higher with longer use
 - May be lower if used < 5 years


Variable	No. of Person-Yr	No. of Breast- Cancer Events	Age-Adjusted Incidence Rate	Adjusted Relative Risk (95% CI)†	Age-Adjusted Risk Difference (95% CI)
			no. of events/100,000 person-yr		no. of events/100,000 person-yr
Never used hormonal contraception	7,815,180	5955	55	1.00 (Reference)	Reference
Used hormonal contraception >6 mo previously	4,348,722	2883	58	1.08 (1.03 to 1.13)	3 (1 to 6)
Current or recent use of combined hormonal contraception					
Oral combined ethinyl estradiol, 50 µg					
Norethisterone	52,895	23	46	1.01 (0.67 to 1.52)	-9 (-30 to 12)
Levonorgestrel	73,125	54	64	1.21 (0.93 to 1.59)	9 (-9 to 27)
Oral combined ethinyl estradiol, 20 to 40 µg					
Norethisterone	153,603	39	67	1.09 (0.80 to 1.50)	12 (-12 to 35)
Levonorgestrel	638,936	380	72	1.33 (1.20 to 1.48)	17 (9 to 25)
Norgestimate	635,732	180	72	1.22 (1.20 to 1.48)	18 (5 to 30)
Desogestrel	1,453,690	368	64	1.12 (1.01 to 1.25)	9 (1 to 17)
Gestodene	2,633,355	705	69	1.20 (1.11 to 1.30)	14 (8 to 20)
Drospirenone	503,700	102	60	1.05 (0.86 to 1.28)	6 (-8 to 20)
Cyproterone	272,804	77	90	1.44 (1.15 to 1.81)	36 (11 to 60)
Estradiol valerate and dienogest	6,380	7	101	1.62 (0.77 to 3.41)	46 (-30 to 122)
Nonoral combined hormonal contraception					
Patch	10,842	2	60	0.85 (0.21 to 3.41)	5 (-1 to 11)
Vaginal ring	91,313	20	53	0.97 (0.62 to 1.50)	-2 (-32 to 28)
Current or recent use of progestin-only products					
Oral contraceptive					
Norethisterone	128,848	78	58	1.00 (0.80 to 1.25)	3 (-10 to 16)
Levonorgestrel	10,547	16	102	1.93 (1.18 to 3.16)	47 (-4 to 99)
Desogestrel	77,847	42	69	1.18 (0.87 to 1.60)	14 (-8 to 36)
Nonoral contraceptive					
Implant	42,217	9	46	0.93 (0.48 to 1.79)	-9 (-42 to 25)
Levonorgestrel-releasing intrauterine system	503,441	571	70	1.21 (1.11 to 1.33)	16 (9 to 22)
Depot medroxyprogesterone acetate	19,308	5	51	0.95 (0.40 to 2.29)	-4 (-49 to 42)

[†] Relative risks were adjusted for age, calendar year, level of education, the polycystic ovary syndrome, endometriosis, parity, and family history of premenopausal breast or ovarian cancer.

Non-contraceptive benefits of COC

- Dysmenorrhea
- Cycle control
- Reduces menstrual blood loss by 40-50%
- Treatment of Menstrual Migraines*
- Improve hirsutism and acne
- may decrease risk of colorectal, endometrial and ovarian cancer

Helping continuation



Combination Contraception

Contraceptive Ring: Nuvaring

- As or more effective than OCP
- No difference in efficacy based on weight*
- Have patient place it in clinic
- Maybe associated with vaginal irritation, expulsion, discomfort during sex

Contraceptive patch: ortho-evra/xulane

- As or more effective than COCs
- Maybe less effective in obese women*
- Slightly increased r/o thromboembolism compared to COC
 - Data contradictory

*Obese Women: Subset analysis

Medroxyprogesterone acetate (Depo)

Weight gain

- Over 36 months gained 5.1kg more than OC users
- Only contraception regularly associated with weight gain

BMD

- Decrease in BMD
- Longer use worsens BMD and may increase r/o fracture
- Reversible in younger patients

Consider in patients with Sickle Cell or Seizures

No difference in efficacy among obese women

Over the counter*



ACOG Practice bulletin #69: Emergency Contraception. Obstet Gynecol 2005; 106:1443.

Levonorgestrel 0.75 mg- take 1 tab and repeat in 12 hours OR Levonorgestrel 1.5- 1 tab in a single dose

- Up to 72 hours post intercourse*
- Failure rate up to 3 %
- \$50


Ella/ulipristal- 1 tab single dose

- Up to 120 hours post intercourse
- Failure rate 1.4%
- \$51



Copper IUD

- Up to 120 hourspost intercourse
- Failure rate <1%



Questions?

COC

- 2-4 pills repeat in 12 hours
- Efficacy not well studied

Twenty-one brands of oral contraceptives that can be used for emergency contraception (EC) in the United States

		Ethinyl Estradiol per dose, microgram			
Plan B∆	Barr	1 white pill	0	0.75	
Ovral	Wyeth- Ayerst	2 white pills	100	0.50	
Ogestrel	Watson	2 white pills	100	0.50	
Cryselle	Barr	4 white pills	120	0.60	
Levora	Watson	4 white pills	120	0.60	
Lo/Ovral	Wyeth- Ayerst	4 white pills	120	0.60	
Low- Ogestrel	Watson	4 white pills	120	0.60	
Levlen	Berlex	4 light orange pills	120	0.60	
Nordette	Wyeth- Ayerst	4 light orange pills	120	0.60	
Portia	Barr	4 pink pills	120	0.60	
Seasonale	Barr	4 pink pills	120	0.60	
Trivora	Watson	4 pink pills	120	0.50	
Tri-Levlen	Berlex	4 yellow pills	120	0.50	
Triphasil	Wyeth- Ayerst	4 yellow pills	120	0.50	
Enpresse	Barr	4 orange pills	120	0.50	
Alesse	Wyeth- Ayerst	5 pink pills	100	0.50	
Lessina	Barr	5 pink pills	100	0.50	
Levlite	Berlex	5 pink pills	100	0.50	
Lutera	Watson	5 white pills	100	0.50	
Aviane	Barr	5 orange pills	100	0.50	
Ovrette	Wyeth- Ayerst	20 yellow pills	0	0.75	
Jolessa	Barr	4 pink pills	120	0.60	
Lybrel	Wyeth- Ayerst	6 yellow pills	120	0.54	
Quasense	Watson	4 white pills	120	0.60	
Seasonique	Duramed	4 blue-green pills	120	0.60	

^{*} The treatment schedule is one dose as soon as possible after unprotected intercourse, and another dose 12 hours later. However, recent research has found that both doses of Plan B or Ovrette can be taken at the same time.



time.

The progestin in Cryselle, Lo/Ovral, Low-Ogestrel, Ogestrel, Ovral, and Ovrette is norgestrel, which contains two isomers, only one of which (levonorgestrel) is bioactive; the amount of norgestrel in each tablet is twice the amount of levonorgestrel. Levonorgestrel regimens also can be formulated by substituting double the amount of norgestrel as is indicated for levonorgestrel. As Plan B is the only dedicated product specifically marketed for emergency contraception in the United States. Preven, a combined emergency contraception pill, is no longer available for the US market. Proven, a combined emergency contraception pill, is no longer available for the US market. Which is the province of the US market. Princeton (10). Reproduced with permission from: ACOG Practice builetin #69: Emergency Contraception. Obstet Gymecol 2005; 106:1443. Copyright © 2005 Lippincot Williams & Wilkins.